Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
How it helps
A comprehensive and dependable information source available to ensure that industry leaders can stay on top of the latest regulatory, legal, market and commercial developments to anticipate potential threats and identify new opportunities.
How it works
A broad network of global expert analysts and journalists you can rely on to provide valuable news and insight from tracking market events and their impacts from around the globe, to help you understand the potential impact of developments and trends on your business. Plus, access to exclusive interviews with key opinion leaders and market movers for insiders-knowledge to keep you ahead of the competition.
Analysis and opinion covers key topic areas such as:
Generics Bulletin
By Chloe Kent 18 Jan 2022
Medicines for Ireland has appointed Accord Healthcare Ireland managing director Padraic O’Brien as chairperson and Teva Ireland director of generic products Paul Neill as vice chairperson of the Irish industry association. The changes come just a few weeks after Ireland implemented its new framework agreement on off-patent pricing.
Generics Bulletin
By David Wallace 18 Jan 2022
WaveData’s compilation of the fastest-rising UK generics prices in December showed several products across multiple presentations more than doubling their average trade prices to independent pharmacists.
Generics Bulletin
By David Wallace 01 Dec 2021
Bio-Thera Solutions had been hoping to become the first Chinese biosimilars developer to win an FDA approval, for its BAT1706 bevacizumab candidate. However, the announced FDA action date for the application has come and gone with no word from the company or regulator.
Generics Bulletin
By Chloe Kent 30 Nov 2021
ANI Pharmaceuticals has completed its acquisition of niche generics specialist Novitium Pharma, securing access to a pipeline of generics and 505(b)(2) candidates that has expanded further since the deal was announced earlier in the year.
Generics Bulletin
By Dean Rudge 02 Nov 2021
Following a recent settlement in Louisiana, Teva has been told by a court in California it is not liable for the state’s opioid crisis, avoiding for now the potential for significant damages.
Generics Bulletin
12 Oct 2021
India leads the ways with the highest number of approved biosimilars.
Topic Clinical Trials Biosimilars
Generics Bulletin
By David Wallace 17 Sep 2021
The EU’s creation of a Health Emergency Response Authority to deal with future health threats has been welcomed by off-patent industry association Medicines for Europe. However, the organization pointed out current policy and regulatory weaknesses that must be addressed if HERA is to be successful.
Generics Bulletin
By David Wallace 14 Sep 2021
The Medicines Patent Pool has announced that the first shipments of dolutegravir under a fresh agreement covering upper-middle-income countries have reached Azerbaijan and Belarus.
Generics Bulletin
By Akriti Seth 14 Sep 2021
India’s Alkem has delivered a strong quarter with a boost in its domestic business on the back of “strong volume-led growth in the acute therapies and faster than market growth in chronic therapies.” However, the company saw a slight YoY decline in the US.
Generics Bulletin
30 Jul 2021
Dr Reddy’s is to press ahead with India filing plans for single-dose COVID-19 vaccine Sputnik Light and also expects to “build on” the Russian partner’s trial in adolescents of the two-dose Sputnik V. The company also pilots a partnered first-of-its-kind cashless digital health offering.
Generics Bulletin
By Akriti Seth 01 Jul 2021
Major Indian pharmaceutical companies including Cipla, Dr Reddy’s, Emcure, Sun and Torrent have entered into a first-of-its-kind collaboration to jointly sponsor, supervise and monitor the clinical trial of the investigational oral anti-viral drug molnupiravir to fight against COVID-19 in India.
Generics Bulletin
By Akriti Seth 22 Jun 2021
After a production setback, Aspen and Johnson & Johnson announce a donation of 300,000 vaccines to South African teachers. Strides partners with Ennaid for an oral COVID drug, while Dr Reddy’s, Lupin, Cipla and Sun Pharma Partner with Eli Lilly for baricitinib in India and Formycon receives approval for early action for its COVID-19 drug.
Generics Bulletin
By Akriti Seth 16 Jun 2021
After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.
Generics Bulletin
By Ian Schofield 11 Jun 2021
As part of its drive to maximize global access to coronavirus vaccines, the Medicines Patent Pool has developed a publicly accessible resource giving information on the patent status of approved and candidate vaccines.
Generics Bulletin
By David Wallace 08 Jun 2021
Celltrion has pushed into another new market with its Remsima SC subcutaneous version of infliximab, launching the innovative biosimilar in Canada.
Generics Bulletin
26 Jul 2022
Generics Bulletin
26 Jul 2022
Generics Bulletin
25 Jul 2022
Generics Bulletin
25 Jul 2022
Generics Bulletin
25 Jul 2022
Generics Bulletin
25 Jul 2022
Generics Bulletin
22 Jul 2022
Generics Bulletin
22 Jul 2022
Generics Bulletin
22 Jul 2022
Generics Bulletin
22 Jul 2022
Generics Bulletin
21 Jul 2022
Generics Bulletin
21 Jul 2022
Generics Bulletin
21 Jul 2022
Generics Bulletin
21 Jul 2022
Generics Bulletin
20 Jul 2022
Aidan specializes in
24+ years of experience
Duncan specializes in
22+ years of experience
Andrea specializes in
19+ years of experience
Biomedtracker provides real-time analysis of major market-moving events in the pharma and biotech industries. With catalyst tracking and expert insights, Biomedtracker helps you stay on top of breaking events, the drugs pipeline, upcoming milestones, companies, and deals – and their impact on the markets you care about.
Successfully navigate the complex worlds of compliance, legislation, policy regulation, and industry developments with the expertise of our worldwide network of expert analysts and journalists.
HBW Insight is a single source of regulatory, legislative, legal and commercial news and insight connecting the dots across 3 sectors, including over the counter medicines, vitamins and dietary supplements, and cosmetics, which have increasing points of intersection, helping you to anticipate global challenges, risks, and opportunities.
Looking for more products Product Finder
Request a Trial
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
Speak to Sales
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Client Services
Contact us for product technical and account support.
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
